MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/180/0.1/19.09.25 | Market Closed - Börse Stuttgart 02:33:38 2024-07-12 pm EDT | ||
| 1.04 EUR | +10.64% |
|
| Current month | -7.14% | ||
| 1 month | -5.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 1.04 | +10.64% |
| 24-07-11 | 0.94 | -11.32% |
| 24-07-10 | 1.06 | +7.07% |
| 24-07-09 | 0.99 | -9.17% |
| 24-07-08 | 1.09 | +2.83% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 02:33 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME817C |
| ISIN | DE000ME817C4 |
| Date issued | 2024-02-01 |
| Strike | 180 $ |
| Maturity | 2025-09-19 (434 Days) |
| Parity | 10 : 1 |
| Emission price | 0.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.24 € |
|---|---|
| Lowest since issue | 0.44 € |
| Spread | 0.01 € |
| Spread % | 0.96% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
980.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-2.43%
- Stock Market
- Warrants
- Warrant
